{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Alexandre M"],"pubmed_abstract":["The role of IgE autoantibodies has been demonstrated in the pathogenesis of bullous pemphigoid for many years. Recently, omalizumab (OMZ), a humanized monoclonal anti-IgE antibody that depletes total serum IgE, has been used off-label in a few case series of bullous pemphigoids demonstrating a rapid efficacy and allowing significant improvements or complete remission as add-on therapy in first-line treatment-resistant patients. Herein, we report the largest retrospective study to evaluate OMZ effectiveness in patients with subepidermal autoimmune blistering diseases. Our series included 13 patients from a single center with bullous pemphigoid or mucous membrane pemphigoid, of whom 7 had mucous membrane involvement. OMZ was added to the unchanged immunosuppressive therapies. Detailed clinic"],"journal":["Frontiers in immunology"],"pagination":["874108"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9065717"],"repository":["biostudies-literature"],"pubmed_title":["Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients."],"pmcid":["PMC9065717"],"pubmed_authors":["Caux F","Prost-Squarcioni C","Alexandre M","Grootenboer-Mignot S","Bohelay G","Le Roux-Villet C","Morin F","Gille T","Soued I"],"additional_accession":[]},"is_claimable":false,"name":"Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients.","description":"The role of IgE autoantibodies has been demonstrated in the pathogenesis of bullous pemphigoid for many years. Recently, omalizumab (OMZ), a humanized monoclonal anti-IgE antibody that depletes total serum IgE, has been used off-label in a few case series of bullous pemphigoids demonstrating a rapid efficacy and allowing significant improvements or complete remission as add-on therapy in first-line treatment-resistant patients. Herein, we report the largest retrospective study to evaluate OMZ effectiveness in patients with subepidermal autoimmune blistering diseases. Our series included 13 patients from a single center with bullous pemphigoid or mucous membrane pemphigoid, of whom 7 had mucous membrane involvement. OMZ was added to the unchanged immunosuppressive therapies. Detailed clinic","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-04T09:10:17.649Z","creation":"2025-04-04T09:10:17.649Z"},"accession":"S-EPMC9065717","cross_references":{"pubmed":["35514989"],"doi":["10.3389/fimmu.2022.874108"]}}